⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for grade 1 follicular lymphoma

Every month we try and update this database with for grade 1 follicular lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic MastocytosisNCT00132015
Chronic Myelopr...
Leukemia
Lymphoma
Nonneoplastic C...
Precancerous Co...
tanespimycin
18 Years - National Institutes of Health Clinical Center (CC)
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT02992522
B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT02992522
B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasNCT03410901
B-Cell Non-Hodg...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Anti-OX40 Antib...
Laboratory Biom...
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasNCT03410901
B-Cell Non-Hodg...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Anti-OX40 Antib...
Laboratory Biom...
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaNCT01239875
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Adult Diffuse M...
Adult Diffuse S...
Adult Grade III...
Adult Immunobla...
Adult Lymphobla...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Splenic Margina...
Waldenstrom Mac...
dendritic cell ...
cryotherapy
pneumococcal po...
laboratory biom...
immunoenzyme te...
immunohistochem...
autologous dend...
18 Years - 90 YearsMayo Clinic
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaNCT02927964
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Folli...
Refractory Foll...
Mantle Cell Lym...
Marginal Zone L...
Ibrutinib
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaNCT01239875
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Adult Diffuse M...
Adult Diffuse S...
Adult Grade III...
Adult Immunobla...
Adult Lymphobla...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Splenic Margina...
Waldenstrom Mac...
dendritic cell ...
cryotherapy
pneumococcal po...
laboratory biom...
immunoenzyme te...
immunohistochem...
autologous dend...
18 Years - 90 YearsMayo Clinic
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasNCT04883437
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Indolent Non-Ho...
Lymphoplasmacyt...
Lymphoprolifera...
Mantle Cell Lym...
Marginal Zone L...
Acalabrutinib
Obinutuzumab
Quality-of-Life...
Questionnaire A...
18 Years - Emory University
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin LymphomaNCT05169658
Non-Hodgkin Lym...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Indolent B-Cell...
Marginal Zone L...
Recurrent Extra...
Refractory Extr...
Mosunetuzumab
Obinutuzumab
Polatuzumab Ved...
18 Years - University of Washington
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaNCT03010358
Anemia
B-Cell Prolymph...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Hairy Cell Leuk...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Entospletinib
Laboratory Biom...
Obinutuzumab
Pharmacological...
18 Years - OHSU Knight Cancer Institute
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaNCT04450173
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Ibrutinib
Obinutuzumab
Venetoclax
18 Years - University of California, Davis
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaNCT02992522
B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Margi...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Transformed Rec...
B-Cell
Lenalidomide
Obinutuzumab
Venetoclax
18 Years - Ohio State University Comprehensive Cancer Center
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's LymphomasNCT03198026
Non-Hodgkin's L...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Abor Stage ...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Indolent Non-ho...
Stage II Spleni...
Stage III Splen...
Stage IV Spleni...
Ibrutinib
Obinutuzumab
Laboratory Biom...
18 Years - Thomas Jefferson University
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaNCT02532257
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
Ann Arbor Stage...
CD20 Positive
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Ibrutinib
Laboratory Biom...
Lenalidomide
Rituximab
18 Years - M.D. Anderson Cancer Center
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaNCT01239875
Cutaneous B-cel...
Extranodal Marg...
Nodal Marginal ...
Adult Diffuse M...
Adult Diffuse S...
Adult Grade III...
Adult Immunobla...
Adult Lymphobla...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Splenic Margina...
Waldenstrom Mac...
dendritic cell ...
cryotherapy
pneumococcal po...
laboratory biom...
immunoenzyme te...
immunohistochem...
autologous dend...
18 Years - 90 YearsMayo Clinic
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaNCT04257578
B-Cell Non-Hodg...
Diffuse Large B...
High Grade B-Ce...
Primary Mediast...
Transformed Fol...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Acalabrutinib
Axicabtagene Ci...
18 Years - University of Washington
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin LymphomaNCT01000753
Adult Immunobla...
Central Nervous...
Childhood Immun...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3 Follicu...
Lymphoprolifera...
Mantle Cell Lym...
Marginal Zone L...
Non-Hodgkin Lym...
Primary Cutaneo...
Primary Cutaneo...
Small Lymphocyt...
Cytology Specim...
- 21 YearsChildren's Oncology Group
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasNCT03410901
B-Cell Non-Hodg...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Small Lymphocyt...
Anti-OX40 Antib...
Laboratory Biom...
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University
Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaNCT02950220
B-Cell Lymphoma...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Mediastinal Lym...
Recurrent B-Cel...
Recurrent Burki...
Recurrent Diffu...
Recurrent Folli...
Recurrent Lymph...
Recurrent Mantl...
Recurrent Margi...
Recurrent Walde...
Refractory B-Ce...
Refractory Burk...
Refractory Diff...
Refractory Foll...
Refractory Lymp...
Refractory Mant...
Ibrutinib
Laboratory Biom...
Pembrolizumab
18 Years - Ohio State University Comprehensive Cancer Center
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaNCT03010358
Anemia
B-Cell Prolymph...
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Hairy Cell Leuk...
Lymphoplasmacyt...
Mantle Cell Lym...
Marginal Zone L...
Recurrent Chron...
Recurrent Small...
Refractory Chro...
Refractory Smal...
Richter Syndrom...
Entospletinib
Laboratory Biom...
Obinutuzumab
Pharmacological...
18 Years - OHSU Knight Cancer Institute
TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaNCT02927964
Grade 1 Follicu...
Grade 2 Follicu...
Grade 3a Follic...
Recurrent Folli...
Refractory Foll...
Mantle Cell Lym...
Marginal Zone L...
Ibrutinib
Radiation Thera...
TLR9 Agonist SD...
18 Years - Stanford University
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: